The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study

Abstract

SummaryBackgroundThe pathophysiology of psychosis is incompletely understood. Disruption in cortical glutamatergic signalling causing aberrant striatal dopamine synthesis capacity is a proposed model for psychosis, but has not been tested in vivo. We therefore aimed to test the relationship between cortical glutamate concentrations and striatal dopamine synthesis capacity, and psychotic symptoms.MethodsIn this cross-sectional multimodal imaging study, 28 individuals with first-episode psychosis and 28 healthy controls underwent 18F-DOPA PET (measuring striatal dopamine synthesis capacity), and proton magnetic resonance spectroscopy (measuring anterior cingulate cortex glutamate concentrations). Participants were recruited from first-episode psychosis services in London, UK and were required to be in the first episode of a psychotic illness, with no previous illness or treatment episodes. Exclusion criteria for all participants were: history of substantial head trauma, dependence on illicit substances, medical comorbidity (other than minor illnesses), and contraindications to scanning (such as pregnancy). Symptoms were measured using the Positive and Negative Syndrome Scale. The primary endpoint was the relationship between anterior cingulate cortex glutamate concentrations and striatal dopamine synthesis capacity in individuals with their first episode of psychosis as shown by imaging, examined by linear regression. Linear regression was used to examine relationships between measures.FindingsGlutamate concentrations showed a significant inverse relationship with striatal dopamine synthesis capacity in patients with psychosis (R2=0·16, p=0·03, β −1·71 × 10−4, SE 0·76 × 10−4). This relationship remained significant after the addition of age, gender, ethnicity, and medication status to the model (p=0·015). In healthy controls, there was no significant relationship between dopamine and glutamate measures (R2=0·04, p=0·39). Positive and Negative Syndrome Scale positive psychotic symptoms were positively associated with striatal dopamine synthesis capacity (R2=0·14, p=0·046, β 2546, SE 1217) and showed an inverse relationship with anterior cingulate glutamate concentrations (R2=0·16, p=0·03, β −1·71 × 10−4, SE 7·63 × 10−5). No relationships were seen with negative symptoms (positive symptoms, mean [SD] −18·4 (6·6) negative symptoms, mean [SD] −15·4 [6·1]).InterpretationThese observations are consistent with the hypothesis that cortical glutamate dysfunction is related to subcortical dopamine synthesis capacity and psychosis. Although the precise mechanistic relationship between cortical glutamate and dopamine in vivo remains unclear, our findings support further studies to test the effect of modulating cortical glutamate in the treatment of psychosis.FundingMedical Research Council, Wellcome Trust, Biomedical Research Council, South London and Maudsley NHS Foundation Trust, JMAS Sim Fellowship, Royal College of Physicians (Edinburgh) (SJ).

Dopamine and glutamate in schizophrenia: biology, symptoms and treatment

“…This is in keeping with the imaging studies discussed above, in which both increased dopamine and glutamate measures were observed in the striatum in schizophrenia, which could potentially result from increased activity of glutamatergic projection to the striatum. Other studies found the same relationship between cortical glutamate and striatal dopamine in clinical high‐risk and first‐episode psychosis patients, but not in controls.…”

In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis

“…Because CB1R binding inhibits calcium entry into the presynaptic neuron via N-, P-, and Q-type calcium channels, 58 , 59 the presence of fewer CB1Rs may dysregulate calcium and potassium channels, leading to neurochemical alterations in psychosis. 34 , 35 , 36 , 60 , 61 Because CB1Rs modulate neurotransmitters implicated in psychosis, including dopamine, 62 glutamate, 63 and γ-aminobutyric acid, 58 future studies are needed to investigate whether CB1R alterations precipitate other neurochemical alterations in psychosis.…”

Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis

“…Another strategy could be to use biomarkers to identify patients who may have TRS to either exclude them or enrich samples for studies of TRS. There is evidence that imaging measures, such as for dopamine, glutamate and resting-state connectivity may be useful for this [74][75][76][77]. A general issue we identified in many studies is limited sample characterisation (e.g.…”